Advanced Drug Delivery Reviews

Advanced Drug Delivery Reviews: A Complete Profile

Advanced Drug Delivery Reviews (ISO 4 abbreviation Adv. Drug Deliv. Rev., CODEN ADDREP) is one of the most influential journals in pharmaceutical science: a reviews-only, peer-reviewed journal published by Elsevier that covers the controlled release and delivery of drugs and other biologically active agents. Founded in 1987, it has published some of the most cited papers in the history of drug delivery — including landmark reviews on the EPR effect in tumor targeting, multifunctional nanocarriers, responsive polymeric delivery systems, and folate-mediated drug delivery. It is the journal many researchers read first when entering the field and the one many cite when framing a new delivery technology.

This profile compiles verifiable facts from the publisher's ScienceDirect pages, standard bibliographic records, and secondary metric sources. Bibliographic identifiers and publication history are drawn from primary records; citation metrics are attributed to their aggregator sources and should be checked against current data before citation.

Publisher, Identifiers, and Publication History

Advanced Drug Delivery Reviews is published by Elsevier (Elsevier B.V., Amsterdam, Netherlands). Its standard identifiers are:

• Print ISSN: 0169-409X
• Online ISSN: 1872-8294
• CODEN: ADDREP
• ISO 4 abbreviation: Adv. Drug Deliv. Rev.
• Library of Congress Control Number: sn87026401; OCLC: 13190647
• Publisher site: sciencedirect.com/science/journal/0169409X

The journal was established in 1987 and has published continuously since. Its publication frequency is 15 issues per year (per standard bibliographic listings). The discipline is pharmacology/pharmaceutical science, and the language is English. Coverage history in aggregator records runs from 1987 to the present.

Editorial Leadership

The editor-in-chief is listed as H. Ghandehari in standard reference sources (attributed to encyclopedic listings; readers should confirm the current masthead on the journal's ScienceDirect page, since editorial appointments change). The journal's editorial board is composed of leading figures in drug delivery, pharmaceutics, biomaterials, and nanomedicine. As a reviews journal, its editorial work centers on commissioning: identifying emerging topics, inviting authoritative authors, and curating themed issues that define the state of a subfield.

Scope: What the Journal Publishes

The journal's scope is the controlled release and delivery of drugs and other biologically active agents — formulation science, delivery technologies, targeting strategies, and the biological barriers that delivery systems must overcome. Although it is a reviews journal, its reviews are substantive and often agenda-setting: they synthesize a field, propose frameworks, and identify the experiments that still need to be done.

Recurring themes across the journal's history include:

• Nanocarriers and nanomedicine — liposomes, polymeric nanoparticles, micelles, dendrimers, inorganic nanosystems, and multifunctional carriers combining therapy with imaging.
• Targeted delivery — ligand-mediated targeting (folate, antibodies, peptides), the EPR effect for macromolecular delivery to solid tumors, and strategies for overcoming biological barriers.
• Stimuli-responsive systems — pH-, temperature-, enzyme-, and light-responsive polymers and materials that release cargo on demand.
• Biologics delivery — delivery of proteins, peptides, nucleic acids (siRNA, mRNA), and gene-editing payloads, including pharmacokinetic considerations for targeted systems.
• Devices and physical methods — microneedles, implants, and devices that use physical forces to disrupt biological barriers.
• Emerging frontiers — recent issues have covered AI and machine learning-guided optimization in drug delivery, organ-on-chip platforms for nanomedicine testing, microfluidic transfection systems, and targeted protein degradation through lysosomal pathways.

Landmark Papers and the Journal's Intellectual Footprint

Few journals can claim as many field-defining papers as Advanced Drug Delivery Reviews. Its 25th-anniversary tribute issue collected the most cited papers in the journal's history, a roster that reads like a syllabus for modern drug delivery. Among the landmark contributions documented on the publisher's pages:

• Hiroshi Maeda, Hideaki Nakamura, and Jun Fang on the EPR effect for macromolecular drug delivery to solid tumors — the conceptual foundation of a generation of cancer nanomedicine.
• Vladimir P. Torchilin on multifunctional nanocarriers — carriers engineered to combine targeting, imaging, and therapy.
• S. Stolnik, L. Illum, and S. S. Davis on long-circulating microparticulate drug carriers and the PEG-coated sterically stabilized nanospheres work of Gref, Domb, Quellec, Blunk, and Langer — foundational to stealth nanoparticle design.
• Joseph Kost and Robert Langer on responsive polymeric delivery systems.
• Yingjuan Lu and Philip S. Low on folate-mediated delivery of macromolecular anticancer agents.
• Rakesh K. Jain on the delivery of molecular and cellular medicine to solid tumors.

These papers are cited not as trivia but as evidence of the journal's role: when a topic matures enough for a definitive review in ADDR, the field treats it as arrived.

Themed Issues and Recent Directions

The journal publishes themed issues that capture emerging directions. Recent volumes (2026) include coverage of microfluidic transfection systems, gas-entrapping materials for damage control, strategies for targeted protein degradation through lysosomal pathways, artificial intelligence and machine learning-guided optimization in drug delivery, nanodrug delivery systems in tumor immunotherapy, matrix-integrated microfluidic tumor models for evaluating delivery systems, organ-on-chip platforms as engines for AI-guided nanomedicine, technology for nucleic acid delivery in hematological malignancies, medicinal gases for central nervous system injuries, synergies between data science and delivery technologies, and bioconjugates for oligonucleotide delivery to the central nervous system.

This trajectory shows the journal tracking the field's migration from classical formulation science toward convergence with data science, microfluidics, immunotherapy, and nucleic-acid therapeutics — while remaining anchored in rigorous review of delivery mechanisms.

Abstracting and Indexing

The journal is abstracted and indexed in a comprehensive set of services, per standard bibliographic records: BIOSIS Previews, CAB Abstracts, Chemical Abstracts, Current Contents/Life Sciences, EMBASE, MEDLINE, Science Citation Index Expanded, and Scopus. This breadth of indexing — spanning chemistry, life sciences, and clinical medicine — reflects the journal's interdisciplinary readership and ensures its reviews are discoverable across the pharmaceutical, chemical, and biomedical literature.

Citation Metrics (Attributed)

Advanced Drug Delivery Reviews is among the highest-impact journals in pharmaceutical science. The following figures are drawn from secondary aggregator sources and should be verified against current Journal Citation Reports and Scopus data before being cited:

• Impact factor 15.47 (2020) — per encyclopedic listings citing Journal Citation Reports.
• Impact score 16.97 (Scopus-based, 2025 vintage) — per Resurchify; the site notes this is computed from Scopus data and may differ from the Clarivate impact factor.
• h-index 386 — per Resurchify (a separate aggregator snapshot lists 348; figures vary by source and date).
• SJR 3.721 — per Resurchify (another snapshot lists 2.982).
• Best quartile Q1 in Pharmaceutical Science — per aggregator records.
• Overall rank ~489–622 across all journals — per aggregator snapshots, varying by year.
• Total citations ~10,348 in a recent three-year window — per aggregator data.

The variation between snapshots underscores a standing rule of this profile series: treat aggregator metrics as directional and verify current figures in the primary sources (Clarivate JCR, Scopus/SCImago) before citing them in formal contexts.

Publishing Model and Access

Advanced Drug Delivery Reviews is published by Elsevier on the ScienceDirect platform. The journal operates a hybrid model: most content is subscription-access, with selected articles published open access (recent issues show a mix of open-access and subscription review articles). Authors considering submission should consult the current guide for authors for article-processing charges for the open-access option, licensing terms, and any institutional agreements.

Peer Review and Editorial Process

As a peer-reviewed journal, ADDR subjects submissions to editorial screening and external peer review. Much of its content is commissioned — editors invite leading researchers to write reviews on topics of strategic importance — but unsolicited review proposals are also considered. The journal's reputation rests on the authority of its authors and the rigor of its editorial curation; a review in ADDR is widely read as the current consensus statement on its topic. Specifics of the review workflow (reviewer numbers, blinding, median timelines) are not verified in this profile.

Readership and Community

The journal's readers include pharmaceutical scientists, formulation scientists, biomaterials researchers, nanomedicine groups, chemical engineers working on delivery systems, and clinicians interested in the translational science of drug delivery. It is a core title for academic libraries supporting pharmacy, pharmaceutics, biomedical engineering, and materials-science programs, and a standard reference for industrial scientists in drug delivery and formulation development.

Guidance for Prospective Authors

• Fit: The journal publishes reviews — comprehensive, critical syntheses — not original research articles. Proposals should identify a topic ripe for synthesis and explain why the timing is right.
• Commissioning: Many reviews are invited; unsolicited proposals should be directed to the editors with a clear outline, the proposed authors' credentials, and a justification of the review's novelty relative to existing literature.
• Authority: Successful reviews typically come from groups with deep publication records in the topic; the journal's brand depends on authoritativeness.
• Open access: Confirm the current open-access article-processing charge and license options in the guide for authors.
• Themed issues: Watch for calls for papers for themed issues aligned with your expertise.

The Commissioned Review: How ADDR Shapes Fields

Advanced Drug Delivery Reviews exercises influence through a mechanism distinct from most journals: the commissioned, agenda-setting review. While many journals passively receive submissions, ADDR's editors actively identify topics at inflection points — a delivery technology maturing from proof-of-concept to clinical translation, a biological barrier whose mechanisms have just become clear, a computational approach newly applicable to formulation — and invite the researchers best positioned to synthesize them. The result is a review that does not merely summarize but organizes: it names the open questions, proposes mechanistic frameworks, and effectively writes the research agenda for the next several years.

This editorial model explains the journal's extraordinary citation performance. A definitive review in ADDR becomes the paper that subsequent primary-research articles cite in their introductions — the "for a review, see…" reference that frames an entire subfield. The journal's most-cited papers share this character: Maeda's EPR-effect review did not just report data but articulated the conceptual basis for tumor-targeted nanomedicine; Torchilin's multifunctional-nanocarrier review mapped a design space that hundreds of groups then explored. For authors, an invitation to write for ADDR is recognition of field leadership; for readers, each issue is a curated briefing on where drug delivery is heading.

A Decade-by-Decade Thematic Map

The founding era (1987–1990s): The journal was established when "controlled release" was maturing from a pharmaceutical specialty into a broader science of delivery. Early coverage centered on polymeric delivery systems, microparticulate carriers, and the pharmacokinetics of sustained release — the foundational work of figures like Robert Langer, whose responsive polymeric delivery systems review remains a landmark.

The nanotechnology wave (2000s): As nanoscience transformed materials research, ADDR became the venue where nanocarriers were theorized and critiqued: long-circulating "stealth" nanoparticles, PEG-coated sterically stabilized nanospheres, multifunctional carriers combining therapy and imaging, and inorganic nanosystems for therapeutic delivery. The journal's pages tracked both the excitement and the emerging skepticism — including influential critiques asking why so many cancer nanomedicines produced papers but few drugs.

Targeting and barriers (2010s): The focus shifted to biological barriers and how to overcome them: receptor-mediated endocytosis pathways, devices using physical forces to disrupt barriers, the interface of drug delivery and tissue engineering, and advanced materials and processing for delivery. The 25th-anniversary tribute issue (2012) canonized the field's most-cited papers and made the journal's historical role explicit.

Convergence (2020s): Recent volumes show drug delivery converging with data science, microfluidics, immunotherapy, and nucleic-acid therapeutics — AI-guided optimization, organ-on-chip testing platforms, tumor-immunotherapy nanodrugs, lysosomal targeted protein degradation, and bioconjugates for CNS oligonucleotide delivery. The through-line across four decades is constant: the journal publishes the reviews that tell the field what it knows and what it must learn next.

For Early-Career Researchers

For doctoral students and postdocs entering drug delivery, ADDR serves as both textbook and map. A practical reading strategy: start with the anniversary and themed issues relevant to your subfield, then trace forward through the citing literature to see how the field responded. Because ADDR reviews are written by leaders, their reference lists are curated bibliographies — often the fastest route to mastering a topic's foundations. When preparing a manuscript for a primary-research journal, citing the relevant ADDR review signals to reviewers that you understand the field's consensus and its open questions. And when your own work matures to the point where you can see the field's shape whole, proposing a review to ADDR's editors is a recognized career milestone.

Distinguishing ADDR from Neighboring Journals

Researchers sometimes confuse Advanced Drug Delivery Reviews with neighboring titles, so the distinctions are worth stating plainly. The Journal of Controlled Release — also an Elsevier title and also central to the field — publishes primary research articles alongside reviews; ADDR publishes reviews only. The International Journal of Pharmaceutics covers the full breadth of pharmaceutics including formulation and manufacturing research; ADDR is narrower and deeper, devoted specifically to delivery science at review length. Drug Delivery and Translational Research emphasizes translation toward the clinic; ADDR's reviews span the entire pipeline from fundamental mechanisms to clinical outlooks. What makes ADDR unique is the combination: a single journal, publishing nothing but authoritative reviews, with the citation impact to match the best primary-research journals in pharmaceutical science. When a topic earns a review here, the field treats it as a milestone.

Frequently Asked Questions

What is Advanced Drug Delivery Reviews? A peer-reviewed, reviews-only journal published by Elsevier since 1987, covering the controlled release and delivery of drugs and biologically active agents.

What are its ISSNs? Print ISSN 0169-409X; online ISSN 1872-8294; CODEN ADDREP.

Does it publish original research? No — it publishes review articles (and commissioned thematic content), not primary research papers.

How often is it published? 15 issues per year, per standard bibliographic listings.

Is it indexed in MEDLINE and Scopus? Yes — it is indexed in MEDLINE, Scopus, Science Citation Index Expanded, EMBASE, Chemical Abstracts, and other major services.

What is its impact factor? Aggregator sources report figures in the mid-teens (for example, 15.47 for 2020); verify the current figure in Journal Citation Reports before citing.

Who should read it? Pharmaceutical scientists, formulation scientists, biomaterials and nanomedicine researchers, and anyone entering drug delivery who needs the field's consensus view.

How do I propose a review? Contact the editors with a clear outline, the proposed authors' credentials, and an explanation of what makes the topic timely — many reviews are commissioned, but strong unsolicited proposals are considered.

Outlook

As drug delivery enters an era defined by nucleic-acid therapeutics, AI-designed formulations, and increasingly precise targeting, the need for authoritative synthesis only grows. Advanced Drug Delivery Reviews is positioned to remain the field's central forum — the journal researchers consult to understand what is known, what is contested, and what comes next. Its continued strength will depend on the same editorial judgment that built its reputation: choosing the right topics, commissioning the right authors, and insisting on reviews that advance understanding rather than merely cataloguing literature. Nearly four decades after its founding, it remains the review journal against which the field measures itself.

Why This Journal Matters

Advanced Drug Delivery Reviews matters because drug delivery is a field where progress is measured in reviews: the distance between a promising material and a clinical product is bridged by synthesis, critique, and framework-building, and this journal has been the principal venue for that work for nearly four decades. Its pages contain the papers that defined stealth nanoparticles, the EPR effect, stimuli-responsive polymers, and targeted nanocarriers — the conceptual infrastructure of modern nanomedicine. For anyone entering pharmaceutical science, reading ADDR is not optional background; it is how the field thinks.

Profile notes: The editor-in-chief attribution (H. Ghandehari) is drawn from encyclopedic listings and should be confirmed on the live journal page. All citation metrics are attributed to their aggregator sources; verify current figures in Clarivate JCR and Scopus/SCImago. Peer-review workflow details and current APC schedules are marked as not publicly disclosed in the sources consulted.